Literature DB >> 15045572

Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions.

Fausto Roila1.   

Abstract

GOALS: In 1996, a gap between the literature evidence for the prevention of chemotherapy-induced emesis and the prescription pattern in clinical practice was demonstrated in a drug utilization study. This study, carried out in 103 Italian oncological centers (77 new; 26 old that participated in the previous study) evaluates three different intervention strategies to implement these guidelines. PATIENTS AND METHODS: In cancer patients submitted to chemotherapy, prescriptions of antiemetics were prospectively monitored for 2 consecutive weeks in 1999. Simple diffusion of guidelines was evaluated in an observational study in the 77 new centers, while the double combination of simple diffusion and "audit and feedback" strategy was randomly compared in the old centers with the triple combination of the same two strategies plus an "educational outreach visit." MAIN
RESULTS: Simple diffusion of guidelines improved the prescription but only for acute and delayed emesis induced by high-moderate emetogenic chemotherapy. No significant difference was detected in the prescriptions against cisplatin-induced emesis. The inappropriate use of 5-HT(3) antagonists for prophylaxis of low emetogenic chemotherapy was found most frequently. Similar poor results were achieved by the audit and feedback strategy, while the educational outreach visit significantly increased the prescription of the optimal prophylaxis for cisplatin-induced acute and delayed emesis.
CONCLUSIONS: A combination of interventions, including an educational outreach visit, seems to be a good strategy for transferring the results of antiemetic research to oncological practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15045572     DOI: 10.1007/s00520-003-0553-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  4 in total

Review 1.  Improving drug prescribing in primary care: a critical analysis of the experimental literature.

Authors:  S B Soumerai; T J McLaughlin; J Avorn
Journal:  Milbank Q       Date:  1989       Impact factor: 4.911

Review 2.  Strategies for improving prescribing practice.

Authors:  G M Anderson; J Lexchin
Journal:  CMAJ       Date:  1996-04-01       Impact factor: 8.262

3.  Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research.

Authors: 
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

Review 4.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).

Authors: 
Journal:  Ann Oncol       Date:  1998-08       Impact factor: 32.976

  4 in total
  14 in total

1.  Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.

Authors:  Ian Olver; Rebecca A Clark-Snow; Enzo Ballatori; Birgitte T Espersen; Emilio Bria; Karin Jordan
Journal:  Support Care Cancer       Date:  2010-08-29       Impact factor: 3.603

2.  Antiemetic prescribing practices using a computerized physician order entry system.

Authors:  Kunal C Kadakia; Alexis D Leal; Drew K Seisler; Rui Qin; Kelliann C Fee-Schroeder; Darryl C Grendahl; Kristine M Sorgatz; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2013-09-13       Impact factor: 3.603

Review 3.  Emesis induced by low or minimal emetic risk chemotherapy.

Authors:  Maurizio Tonato; Rebecca A Clark-Snow; David Osoba; Albano Del Favero; Enzo Ballatori; Sussanne Borjeson
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

4.  Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan.

Authors:  Ayako Okuyama; Fumiaki Nakamura; Takahiro Higashi
Journal:  Support Care Cancer       Date:  2014-02-14       Impact factor: 3.603

5.  Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.

Authors:  Michelino De Laurentiis; Chiara Bonfadini; Vito Lorusso; Giuseppina Cilenti; Francesca Di Rella; Giuseppe Altavilla; Manuela Otero; Antonio Ardizzoia; Paolo Marchetti; Giorgia Peverelli; Domenico Amoroso; Stefania Vecchio; Elena Fiorio; Simona Orecchia
Journal:  Support Care Cancer       Date:  2018-06-25       Impact factor: 3.603

6.  Integrating referral to community-based cancer information and support services in a hospital setting.

Authors:  David J T Marco; Anna G Boltong; Adrian Dabscheck; Georgina Akers; Michelle Pryce; Victoria M White
Journal:  Support Care Cancer       Date:  2017-09-17       Impact factor: 3.603

Review 7.  Supportive care treatment guidelines: value, limitations, and opportunities.

Authors:  Douglas E Peterson; Rene-Jean Bensadoun; Rajesh V Lalla; Deborah B McGuire
Journal:  Semin Oncol       Date:  2011-06       Impact factor: 4.929

8.  Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children's Oncology Group.

Authors:  Priya Patel; Paula D Robinson; Andrea Orsey; Jason L Freedman; Anne-Marie Langevin; Debbie Woods; Lillian Sung; L Lee Dupuis
Journal:  Pediatr Blood Cancer       Date:  2016-01-27       Impact factor: 3.167

9.  Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.

Authors:  Mary Lou Affronti; Susan M Schneider; James E Herndon; Susan Schlundt; Henry S Friedman
Journal:  Support Care Cancer       Date:  2014-02-26       Impact factor: 3.603

Review 10.  Delayed emesis: moderately emetogenic chemotherapy.

Authors:  Fausto Roila; David Warr; Rebecca A Clark-Snow; Maurizio Tonato; Richard J Gralla; Lawrence H Einhorn; Jorn Herrstedt
Journal:  Support Care Cancer       Date:  2004-11-12       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.